查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466015

幹細胞治療市場：依類型、細胞來源、治療應用、最終使用者、預測（2024-2030）

Stem Cell Therapy Market by Type, Cell Source, Therapeutic Application, End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年全球幹細胞治療市場規模為4.3983億美元，2024年達4.9323億美元，2030年將達10.2744億美元，複合年成長率為12.88%。

幹細胞療法是指在醫學上利用幹細胞來取代和修復受損的組織和器官。透過刺激身體的修復機制，這種治療方法對於治療多種疾病非常重要，包括帕金森氏症、阿茲海默症、糖尿病和心臟病。幹細胞有潛力在生命的早期階段和生長過程中產生體內各種類型的細胞。慢性病的流行和政府積極的再生治療措施正在增加全世界對幹細胞治療的需求。然而，高成本、嚴格的監管以及圍繞核准流程的擔憂給主要企業帶來了重大挑戰。公司正試圖透過遵守政府施加的嚴格標準來在這一領域保持敏捷。此外，再生醫學領域的重大發展和持續的研發活動正在為主要企業未來的業務擴張做出貢獻。

主要市場統計
基準年[2023] 4.3983億美元
預計年份 [2024] 4.9323 億美元
預測年份 [2030] 10.2744億美元
複合年成長率（%） 12.88%

類型：在慢性病治療中擴大使用同種異體和自體幹細胞療法

同種異體移植是一種將幹細胞從捐贈者移植到另一個接受者的治療方法。當患者的細胞不適合治療時，例如遺傳性疾病，這種治療方法通常是首選。它還具有易於獲得並允許快速治療的優點。另一方面，自體幹細胞療法使用從患者的骨髓、脂肪組織或血液中提取的幹細胞。這種類型的治療方法免疫排斥的風險較低，因為細胞取自患者體內。

細胞來源：在組織重塑和組織修復中擴大採用 AD-MSC 和 BM-MSC

脂肪組織間質幹細胞（AD-MSC）是從脂肪組織（通常稱為體脂肪）中獲得的。這些細胞引起了人們極大的興趣，因為它們相對容易獲得。 AD-MSC 的萃取比其他來源需要更少的侵入性操作，並且可以在局部麻醉下透過抽脂手術進行。 AD-MSC 可分化為多種細胞類型、分泌生長因子並調節免疫反應，因此可用於多種治療方法。同時，從骨髓（通常是骨盆的髂嵴）中間質幹細胞（BM-MSC）。 BM-MSC 是廣泛研究的幹細胞之一，已知具有分化成骨、軟骨和脂肪組織的潛力。 BM-MSC 還具有強大的免疫調節特性，使其成為治療自體免疫疾病和支持骨髓移植植入的有力候選者。另一方面，胎盤臍帶間間質幹細胞（PC-UC-MSC）是在出生後從胎盤和臍帶中獲得的。這些細胞可以非侵入性地收穫，並且與 AD-MSC 和 BM-MSC 等成體幹細胞相比具有較高的增殖率。

治療應用：再生醫學在各個治療領域日益普及

幹細胞被認為是治療各種心血管疾病（包括心肌梗塞和鬱血性心臟衰竭）的突破性選擇。基於幹細胞的手術有可能再生受損的心臟組織、改善心臟功能並刺激心臟細胞修復。在狼瘡和類風濕性關節炎等疾病中，硬化幹細胞療法可以改變疾病進程並恢復免疫平衡。這些細胞可以調節 T 細胞反應，並已用於治療某些自體免疫疾病。幹細胞療法可望再生軟骨、骨骼和肌肉組織，以治療骨關節炎、肌肉萎縮症萎縮症和其他肌肉骨骼疾病。這種治療方法旨在減輕疼痛、改善功能，並延遲或避免關節重建手術等侵入性治療的需要。幹細胞療法治療阿茲海默症神經系統疾病的潛力在於其保護、修復和取代神經細胞和神經膠質細胞的能力。幹細胞已顯示出促進傷口癒合的重要能力。透過在傷口護理中使用間質幹細胞，這些細胞可以促進皮膚組織再生、減少疤痕並縮短癒合時間。這對於燒燙傷患者、糖尿病潰瘍患者以及創傷治療緩慢的患者尤其重要。

最終用戶：學術研究中心和醫院更多地使用幹細胞療法，以提供有效、安全和標準化的治療結果

學術和研發中心對於推進幹細胞科學至關重要，需要各種幹細胞來推進疾病研究、藥物開發和突破性治療方法的開發。這些機構對開創性研究做出了重大貢獻，並且是幹細胞應用創新的溫床。另一方面，門診手術中心（ASC）為某些類型的門診幹細胞治療提供了一個場所。這些中心比醫院需要更少的資源，使它們成為患者和付款人的具有成本效益的選擇。醫院和診所仍然是幹細胞治療的主要場所，特別是對於複雜和急性疾病。醫院和診所服務的患者的多樣性推動了對各種幹細胞治療的需求，包括針對白血病和淋巴瘤等疾病的造血幹細胞移植（HSCT）以及各種再生醫學應用。生物製藥公司在幹細胞療法的開發和商業化中發揮著重要作用。他們購買幹細胞不僅用於研究和開發目的，例如發現新藥和開發再生醫學，而且還用於製造目的，利用幹細胞株大規模生產治療產品。生物製藥公司對幹細胞療法的興趣與其不斷尋找比現有藥物提供更好治療效果的創新治療方法是一致的。生物製藥公司正在致力於幹細胞療法的開發和商業化。購買幹細胞不僅用於研究和開發目的，例如發現新藥和開發再生醫學，而且還用於製造目的，其中幹細胞株用於大規模生產治療產品。

區域洞察

美國和加拿大等國家擁有發達的醫療保健基礎設施和較高的慢性病發病率，增加了對幹細胞療法等創新治療方法的需求。客戶的購買行為反映了採用新醫療保健技術的強烈趨勢，特別是在再生醫學等領域。該地區在幹細胞專利方面的領先地位支持了強大且不斷發展的治療市場，大量的研究投資和活動證明了這一點。歐盟（EU）為幹細胞治療提供了多元化的空間，德國、英國和法國等國家則專注於研究和臨床應用。同時，由於在改善醫療保健方面的大量投資以及對先進醫學的需求不斷增加，中東和非洲對幹細胞療法的興趣正在迅速增加。杜拜細胞治療和再生醫學框架等舉措旨在將該地區定位為幹細胞治療醫療旅遊中心。同時，在亞洲，中國、日本和印度等國家的幹細胞治療市場迅速擴大，政府的支持性政策為研究和創新創造了蓬勃發展的環境。日本和中國擁有快速核准再生醫學產品的先進法規，使這些國家成為採用幹細胞療法的主要空間。在印度，醫療保健基礎設施正在改善，公共和私人研究經費正在增加，幹細胞治療的使用正在擴大，並且正在轉向研究和開發。

FPNV定位矩陣

FPNV定位矩陣對於評估幹細胞治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對幹細胞治療市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，以獲得市場競爭優勢。

本報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.幹細胞治療市場的市場規模與預測是多少？

2.幹細胞治療市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3. 幹細胞治療市場的技術趨勢和法規結構是什麼？

4.幹細胞治療市場主要廠商的市場佔有率是多少？

5. 進入幹細胞治療市場的合適形式和策略性手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地退化性疾病和癌症的發生率正在上升
      • 世界各地政府圍繞幹細胞治療的措施增加
      • 幹細胞治療中心和診所擴建
    • 抑制因素
      • 實施幹細胞治療的困難
    • 機會
      • 幹細胞治療的持續進展
      • 幹細胞療法和治療方法的銷售和臨床試驗核准正在迅速增加
    • 任務
      • 幹細胞治療的倫理與安全問題
  • 市場區隔分析
    • 類型：在慢性病治療中擴大使用同種異體和自體幹細胞療法
    • 細胞來源：在組織重塑和組織修復中擴大採用 AD-MSC 和 BM-MSC
    • 治療應用：再生醫學在各個治療領域日益普及
    • 最終用戶：學術研究中心和醫院更多地使用幹細胞療法，以提供有效、安全和標準化的治療結果
  • 市場趨勢分析
    • 嚴格的基於幹細胞治療的研究舉措、不斷發展的法規結構以及對先進治療方法不斷成長的需求正在推動美洲市場的發展
    • 亞太國家的政府資助和醫療旅遊實踐增加了幹細胞療法的採用，推動了幹細胞療法的進步
    • 由政府資助的學術機構和生物技術公司組成的強大網路加速了歐洲、中東和非洲的幹細胞研究和商業化
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析

第6章幹細胞治療市場：依類型

  • 同種異體幹細胞療法
  • 自體幹細胞治療

第7章幹細胞治療市場：細胞來源

  • 脂肪組織來源的 MSC
  • 骨髓間質幹細胞
  • 胎盤/臍帶來源的 MSC

第8章幹細胞治療市場：依治療應用分類

  • 心血管疾病手術
  • 發炎疾病/自體免疫疾病
  • 肌肉骨骼疾病
  • 神經系統疾病
  • 整形外科和風濕病學
  • 傷口和傷害

第9章幹細胞治療市場：依最終使用者分類

  • 學術研究中心
  • 門診手術中心
  • 生技/製藥公司
  • 醫院/診所

第10章美洲幹細胞治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太幹細胞治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲幹細胞治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 市場佔有率分析（2023）
  • FPNV定位矩陣（2023）
  • 競爭情境分析
    • FUJIFILM投資2億美元用於細胞療法生產
    • FDA 拒絕後 Mesoblast 開始合作進行 SR-aGVHD 試驗
    • Selecta Biosciences 宣布與 Cartesian Therapeutics 合併
    • Takara Bio 與 Fondazione Telethon ETS 簽署 RetroNectin授權合約
    • 拜耳開設第一家細胞療法製造工廠，推動全球再生醫學發展
    • 諾和諾德基金會投資1.35億美元建造細胞治療工廠
    • BioLineRx 宣布 FDA核准APHEXDA（莫替沙福肽）與Filgrastim（G-CSF）聯合用於多發性骨髓瘤患者的造血幹細胞採集和隨後的自體移植
    • BlueRock Therapeutics 和 bit.bio 宣布就基於調節性 T 細胞 (Treg) 的治療治療方法發現和製造達成合作和選擇權協議
    • StemCyte與美國領先的免疫細胞治療公司簽署合作協議，為同種異體工程細胞療法提供藥物製造原料
    • CIRM 投資 8,900 萬美元用於幹細胞和基因治療研究
    • 百時美施貴寶在美國開設新的病毒載體生產工廠，增強細胞治療能力
    • 諾和諾德擴大在大都會圈的研發足跡
    • Garuda Therapeutics 獲得 6,200 萬美元 B 輪資金籌措，用於推進現成的血液幹細胞技術平台
    • BioCardia 和 CellProthera 加強合作，開發 ProtheraCytes，用於治療歐洲的急性心肌梗塞，並有可能為患者提供早期治療機會
    • ReLive Biotechnologies Ltd. 完成對 Co.Don AG 資產的收購和 SHC主導的A 輪資金籌措，進一步實現成為全球再生療法公司的雄心

第14章競爭組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-431752EA49AD

[195 Pages Report] The Stem Cell Therapy Market size was estimated at USD 439.83 million in 2023 and expected to reach USD 493.23 million in 2024, at a CAGR 12.88% to reach USD 1,027.44 million by 2030.

Stem cell therapy refers to the medical use of stem cells to replace and repair damaged or diseased tissue or organs. This therapy is important in treating various diseases, including Parkinson's, Alzheimer's, diabetes, and heart disease, by stimulating the body's repair mechanisms. Stem cells can potentially develop many different cell types in the body during early life and growth. The prevalence of chronic diseases and favorable government initiatives for regenerative treatments worldwide boost the need for stem cell therapy. However, the concerns associated with the high cost, stringent regulations, and approval processes are a significant challenge for the key players. Companies are trying to comply with the robust standards imposed by the governments to remain agile within the spaces. Moreover, the advancements in regenerative therapy and the continuous research and development activities in stem cell therapy contribute to the future expansion of key players.

KEY MARKET STATISTICS
Base Year [2023] USD 439.83 million
Estimated Year [2024] USD 493.23 million
Forecast Year [2030] USD 1,027.44 million
CAGR (%) 12.88%

Type: Increasing uses of allogeneic and autologous stem cell therapy in chronic disease treatments

Allogeneic stem cell therapy involves the transplantation of stem cells from a donor to another recipient. This therapy is often preferred in conditions for patients with cells unsuitable for therapy, such as in cases with genetic disorders. It also allows for off-the-shelf solutions, leading to rapidness in treatment administration. On the other hand, autologous stem cell therapy uses a patient's stem cells collected from their bone marrow, adipose tissue, and blood. This type of therapy is associated with a lower risk of immune rejection since the cells are derived from the patient's body.

Cell Source: Rising adoption of AD-MSCs and BM-MSCs in tissue remodeling and tissue repairing

Adipose tissue-derived mesenchymal stem cells (AD-MSCs) are obtained from adipose tissue, commonly known as body fat. These cells are of significant interest due to their relative ease of access. The extraction of AD-MSCs involves less invasive procedures than other sources and can be done under local anesthesia via liposuction. AD-MSCs are used in various therapeutic approaches because they differentiate into multiple cell types, secrete growth factors, and modulate immune responses. At the same time, bone marrow-derived mesenchymal stem cells (BM-MSCs) are harvested from the bone marrow, typically from the iliac crest of the pelvis. They are among the extensively studied stem cells with known potential to differentiate into bone, cartilage, and adipose tissue. BM-MSCs also have robust immunomodulatory properties, making them prominent candidates for treating autoimmune diseases and supporting engraftment in bone marrow transplantation. While, placental and umbilical cord-derived mesenchymal stem cells (PC-UC-MSCs) are obtained from the placenta and the umbilical cord following childbirth. These cells are non-invasive to collect and have a higher proliferation rate than adult stem cells, such as AD-MSCs and BM-MSCs.

Therapeutic Application: Growing popularity of regenerative medicine in varied therapeutics areas

Stem cells are being explored as a revolutionary option in the treatment of various cardiovascular diseases, including myocardial infarction and congestive heart failure. Procedures utilizing stem cells have the potential to regenerate damaged heart tissue, improve heart function, and stimulate the repair of cardiac cells. In diseases including lupus and rheumatoid arthritis, sclerosis stem cell therapy can modify the disease process and restore immune balance. These cells can modulate T-cell responses and have been used to treat certain autoimmune diseases. For conditions such as osteoarthritis, muscular dystrophy, and other musculoskeletal disorders, stem cell therapy is promising for regenerating cartilage, bone, and muscle tissues. The treatment aims to reduce pain, improve function, and possibly delay or avoid the need for more invasive treatments like joint replacements. Stem cell therapy's potential to treat neurological disorders such as Alzheimer's is its capacity to protect, repair, or replace neurons and glial cells. Stem cells demonstrate a significant capacity to enhance the healing of wounds and injuries. By deploying MSCs in wound care, these cells can promote the regeneration of skin tissue, reduce scarring, and improve healing times. This is particularly relevant for burn victims, patients with diabetic ulcers, or individuals who experience slow wound healing.

End-User: Increasing uses of stem cell therapy in academics & research centers and hospitals offering effective, safe, and standardized treatment outcomes

Academic & research centers are crucial in advancing stem cell science and require various stem cell types to propel disease study, medication development, and therapy innovation breakthroughs. These institutions significantly contribute to pioneering studies and serve as a breeding ground for innovation in stem cell applications. On the other hand, ambulatory surgical centers (ASCs) provide a setting for certain types of outpatient stem cell therapies. These centers, less resource-intensive than hospitals, offer a cost-effective alternative for patients and insurers. Hospitals and clinics remain the primary care setting for the administration of stem cell therapies, particularly for more complex and acute medical conditions. The diverse patient population they serve creates a need for a broad range of stem cell therapies, including hematopoietic stem cell transplantation (HSCT) for diseases such as leukemia and lymphoma and various regenerative medicine applications. Biopharmaceutical companies are key players in the development and commercialization of stem cell therapies. They not only purchase stem cells for R&D purposes - working on new drug discoveries and development of regenerative medicine - but also for the purpose of manufacturing, where stem cell lines are used to produce therapeutic products at scale. Biopharma's interest in stem cell therapies corresponds with its ongoing search for innovative treatments that offer improved outcomes over existing medicines. Biopharmaceutical companies work on the development and commercialization of stem cell therapies. They purchase stem cells for R&D purposes to on new drug discoveries and the development of regenerative medicine and also for the purpose of manufacturing, where stem cell lines are used to produce therapeutic products at scale.

Regional Insights

In America, countries including the United States and Canada, advanced healthcare infrastructure and a high prevalence of chronic diseases have driven the need for innovative treatments such as stem cell therapy. The customer purchasing behavior reflects a greater propensity to adopt new healthcare technologies, particularly in areas such as regenerative medicine. Significant research investments and activity are evidenced by the region's major position in stem cell patents, which supports a robust and evolving therapy market. The European Union (EU) presents a diverse space for stem cell therapy, with countries including Germany, the UK, and France focusing on research and clinical applications. At the same time, the Middle East and Africa region is experiencing burgeoning interest in stem cell therapy with the huge investments in healthcare improvements and increased demand for advanced medical treatments. Initiatives such as the Dubai Cell Therapy and Regenerative Medicine Framework aim to position the region as a hub for medical tourism in stem cell therapy. Meanwhile, in Asia, countries such as China, Japan, and India reflect a rapidly expanding market for stem cell therapies, and the government's supportive policies have resulted in a flourishing environment for research and innovation. Japan's and China's progressive regulatory approach with the establishment of fast-track approval for regenerative medicine products has made these countries major spaces for stem cell therapy adoption. In India, growing healthcare infrastructure and increased public and private funding for research represent a shift towards greater usage and development of stem cell therapies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Stem Cell Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Stem Cell Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Stem Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., Anterogen Co., Ltd., Astellas Pharma Inc., Athersys, Inc., Aurion Biotechnologies, Beike Biotechnology Co., Ltd., BrainStorm Cell Therapeutics Inc., Bristol-Myers Squibb Company, CellProthera, Fate Therapeutics, Inc., Gamida Cell Ltd., Garuda Therapeutics, Holostem Terapie Avanzate S.r.l., Jasper Therapeutics, Inc., JCR Pharmaceuticals Co., Ltd., Juvena Therapeutics Inc., Kangstem Biotech., Ltd., Kite Pharma, Inc. by Gilead Sciences, Inc., Lineage Cell Therapeutics, Inc., Lonza Group AG, Mesoblast Ltd., Novo Nordisk A/S, Plasticell, ReNeuron Group PLC, Sartorius CellGenix GmbH, SQZ Biotechnologies Company, Takara Bio Inc., U.S. Stem Cell Inc, Umoja Biopharma, and Vericel Corporation.

Market Segmentation & Coverage

This research report categorizes the Stem Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Allogeneic Stem Cell Therapy
    • Autologous Stem Cell Therapy
  • Cell Source
    • Adipose Tissue-Derived MSCs
    • Bone Marrow-Derived MSCs
    • Placental / Umbilical Cord-Derived MSCs
  • Therapeutic Application
    • Cardiovascular Diseases Surgeries
    • Inflammatory & Autoimmune Diseases
    • Musculoskeletal Disorders
    • Neurological Disorders
    • Orthopedics & Rheumatoid
    • Wounds & Injuries
  • End-User
    • Academic & Research Centers
    • Ambulatory Surgical Centers
    • Biotechnology & Pharmaceutical Companies
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Stem Cell Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Stem Cell Therapy Market?

3. What are the technology trends and regulatory frameworks in the Stem Cell Therapy Market?

4. What is the market share of the leading vendors in the Stem Cell Therapy Market?

5. Which modes and strategic moves are suitable for entering the Stem Cell Therapy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of degenerative diseases and cancer cases across the world
      • 5.1.1.2. Increasing government initiatives for stem cell therapy across the world
      • 5.1.1.3. Expansion of stem cell therapy centers and clinics
    • 5.1.2. Restraints
      • 5.1.2.1. Difficulties associated with performing stem cell therapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in stem cell therapy
      • 5.1.3.2. Surging approvals for marketing and clinical trials for stem cell therapies and treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical and safety issues of stem cell-based therapy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Increasing uses of allogeneic and autologous stem cell therapy in chronic disease treatments
    • 5.2.2. Cell Source: Rising adoption of AD-MSCs and BM-MSCs in tissue remodeling and tissue repairing
    • 5.2.3. Therapeutic Application: Growing popularity of regenerative medicine in varied therapeutics areas
    • 5.2.4. End-User: Increasing uses of stem cell therapy in academics & research centers and hospitals offering effective, safe, and standardized treatment outcomes
  • 5.3. Market Trend Analysis
    • 5.3.1. Rigorous stem cell therapy based research initiatives, evolving regulatory frameworks, and an increasing demand for advanced therapies is fueling market in Americas
    • 5.3.2. Advancements in stem cell therapies backed by government fundings and rising adoption due to medical tourism practices in the APAC countries
    • 5.3.3. Strong network of academic institutions and biotech firms backed by government funding to accelerate stem cell research and commercialization in EMEA
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Stem Cell Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Allogeneic Stem Cell Therapy
  • 6.3. Autologous Stem Cell Therapy

7. Stem Cell Therapy Market, by Cell Source

  • 7.1. Introduction
  • 7.2. Adipose Tissue-Derived MSCs
  • 7.3. Bone Marrow-Derived MSCs
  • 7.4. Placental / Umbilical Cord-Derived MSCs

8. Stem Cell Therapy Market, by Therapeutic Application

  • 8.1. Introduction
  • 8.2. Cardiovascular Diseases Surgeries
  • 8.3. Inflammatory & Autoimmune Diseases
  • 8.4. Musculoskeletal Disorders
  • 8.5. Neurological Disorders
  • 8.6. Orthopedics & Rheumatoid
  • 8.7. Wounds & Injuries

9. Stem Cell Therapy Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Centers
  • 9.3. Ambulatory Surgical Centers
  • 9.4. Biotechnology & Pharmaceutical Companies
  • 9.5. Hospitals & Clinics

10. Americas Stem Cell Therapy Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Stem Cell Therapy Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Stem Cell Therapy Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Fujifilm to Invest USD 200 Million in Cell Therapy Production
    • 13.3.2. Mesoblast Enters Collaboration for SR-aGVHD Trial After FDA Rejections
    • 13.3.3. Selecta Biosciences Announces Merger with Cartesian Therapeutics
    • 13.3.4. Takara Bio Enters into a License Agreement of RetroNectin with Fondazione Telethon ETS
    • 13.3.5. Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale
    • 13.3.6. Novo Nordisk Foundation Invests USD 135 Million to Build Cell Therapy Plant
    • 13.3.7. BioLineRx Announces FDA Approval of APHEXDA (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma
    • 13.3.8. BlueRock Therapeutics and bit.bio Announce Collaboration and Option Agreement for the Discovery and Manufacture of Regulatory T Cell (Treg) based Therapies
    • 13.3.9. StemCyte Signs a Cooperation Agreement with a Cutting-edge U.S. immune Cell Therapy Company to Supply Drug Preparation Raw Materials for Allogeneic Modified Cell Therapy
    • 13.3.10. CIRM Invests USD 89 Million in Stem Cell and Gene Therapy Research
    • 13.3.11. Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
    • 13.3.12. Novo Nordisk to Expand R&D Presence in Greater Boston Area
    • 13.3.13. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
    • 13.3.14. BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients
    • 13.3.15. ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, Furthering its Ambition to Become the Global Player in Regenerative Therapies

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. STEM CELL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. STEM CELL THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. STEM CELL THERAPY MARKET DYNAMICS
  • FIGURE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. STEM CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. STEM CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. STEM CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC STEM CELL THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC STEM CELL THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS STEM CELL THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS STEM CELL THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BONE MARROW-DERIVED MSCS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BONE MARROW-DERIVED MSCS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PLACENTAL / UMBILICAL CORD-DERIVED MSCS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PLACENTAL / UMBILICAL CORD-DERIVED MSCS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES SURGERIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES SURGERIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ORTHOPEDICS & RHEUMATOID, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ORTHOPEDICS & RHEUMATOID, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL STEM CELL THERAPY MARKET SIZE, BY WOUNDS & INJURIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL STEM CELL THERAPY MARKET SIZE, BY WOUNDS & INJURIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 69. BRAZIL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 70. BRAZIL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 75. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 76. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 77. CANADA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 78. CANADA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 83. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 84. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 85. MEXICO STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 86. MEXICO STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 93. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 94. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 95. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 96. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 112. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 114. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 119. CHINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 120. CHINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 121. CHINA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 122. CHINA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 127. INDIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 128. INDIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 129. INDIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 130. INDIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 135. INDONESIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 136. INDONESIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 137. INDONESIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 138. INDONESIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 143. JAPAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 144. JAPAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 145. JAPAN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 146. JAPAN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 151. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 152. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 153. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 154. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 160. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 162. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 167. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 168. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 169. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 170. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 176. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 178. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 183. TAIWAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. TAIWAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. TAIWAN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 186. TAIWAN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 191. THAILAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 192. THAILAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 193. THAILAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 194. THAILAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 199. VIETNAM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 200. VIETNAM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 201. VIETNAM STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 202. VIETNAM STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 217. DENMARK STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 218. DENMARK STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 219. DENMARK STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 220. DENMARK STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 225. EGYPT STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 226. EGYPT STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 227. EGYPT STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 228. EGYPT STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 233. FINLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 234. FINLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 235. FINLAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 236. FINLAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 241. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 242. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 243. FRANCE STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 244. FRANCE STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 249. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. GERMANY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 252. GERMANY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 257. ISRAEL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 258. ISRAEL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 259. ISRAEL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 260. ISRAEL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 265. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 266. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 267. ITALY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 268. ITALY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 274. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 275. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 276. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 281. NIGERIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 282. NIGERIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 283. NIGERIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 284. NIGERIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 289. NORWAY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 290. NORWAY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 291. NORWAY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 292. NORWAY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 297. POLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 298. POLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 299. POLAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 300. POLAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 305. QATAR STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 306. QATAR STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 307. QATAR STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 308. QATAR STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. RUSSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 312. RUSSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 313. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 314. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 315. RUSSIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 316. RUSSIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 320. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 322. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 323. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 324. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 328. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 330. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 331. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 332. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 333. SPAIN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 334. SPAIN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 335. SPAIN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 336. SPAIN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 337. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 338. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 339. SPAIN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 340. SPAIN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 341. SWEDEN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 342. SWEDEN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 343. SWEDEN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 344. SWEDEN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 345. SWEDEN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 346. SWEDEN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 347. SWEDEN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 348. SWEDEN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 350. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 351. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 352. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)